Depósito Digital de Documentos de la UAB Encontrados 12 registros  anterior11 - 12  ir al registro: La búsqueda tardó 0.02 segundos. 
11.
6 p, 225.1 KB Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial / Sclafani, F. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Chau, I. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Cunningham, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Peckitt, C. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Lampis, A. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Hahne, J. C. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Braconi, C. (The Institute of Cancer Research. Division of Cancer Therapeutics (UK)) ; Tabernero Caturla, Josep (Hospital Universitari Vall d'Hebron) ; Glimelius, B. (University of Uppsala. Department of Immunology, Genetics and Pathology (Sweden)) ; Cervantes, A. (Universidad de Valencia. Departamento de Hematología y Oncología Médica) ; Begum, R. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Gonzalez De Castro, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Hulkki Wilson, S. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Eltahir, Z. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Wotherspoon, A. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Tait, D. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Brown, G. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Oates, J. (The Royal Marsden NHS Foundation Trust. Department of Medicine (UK)) ; Valeri, N. (The Institute of Cancer Research. Division of Molecular Pathology (UK)) ; Universitat Autònoma de Barcelona
Lethal-7 (let-7) is a tumour suppressor miRNA which acts by down-regulating several oncogenes including KRAS. A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. [...]
2015 - 10.1093/annonc/mdv285
Annals of Oncology, Vol. 26, Issue 9 (September 2015) , p. 1936-1941  
12.
6 p, 263.8 KB A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer / Tan, E.H. (National Cancer Centre (Singapur). Department of Medical Oncology) ; Ramlau, R. (Regional Lung Disease Centre (Poznan). Department of Oncology) ; Pluzanska, A. (Regional Oncology Centre (Lodz, Polònia). Oncological Chemotherapy Clinic) ; Kuo, H. -P. (Chang Gung Memorial Hospital (Linkou, Taiwan). Department of Thoracic Medicine) ; Reck, M. (Hospital Grosshansdorf (Grosshansdorf, Alemanya). Department of Thoracic Oncology) ; Milanowski, J. (Akademia Medyczna w Lublinie (Lublin, Polònia). Department of Pneumology, Oncology and Allergology) ; Au, J. S. -K. (Queen Elizabeth Hospital (Hong Kong). Department of Clinical Oncology) ; Felip Font, Enriqueta (Hospitals Vall d'Hebron (Barcelona, Catalunya)) ; Yang, P. -C. (National Taiwan University Hospital (Taipei, Taiwan)) ; Damyanov, D. (Specialized Hospital for Active Treatment in Oncology (Sofia, Bulgaria)) ; Orlov, S. (Pavlov State Medical University. Research Institute of Pulmonology (Sant Petersburg, Rússia)) ; Akimov, M. (Hoffmann-La Roche (Basel, Suïssa)) ; Delmar, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Essioux, L. (Hoffmann-La Roche (Basel, Suïssa)) ; Hillenbach, C. (Hoffmann-La Roche (Basel, Suïssa)) ; Klughammer, B. (Hoffmann-La Roche (Basel, Suïssa)) ; McLoughlin, P. (Hoffmann-La Roche (Basel, Suïssa)) ; Baselga Torres, Josep, 1959-, (Vall d'Hebron Hospitals)
Background: Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. [...]
2010
Annals of oncology, Vol. 21, Issue 2 (2010) , p. 217-222  

Depósito Digital de Documentos de la UAB : Encontrados 12 registros   anterior11 - 12  ir al registro:
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.